Business context and reporting period
This is Cactus Ventures, Inc.’s Form 10-K for the fiscal year ended December 31, 2012—not a quarterly filing. Although the request identifies Actinium Pharmaceuticals, Inc., the filing is issued by Cactus, which closed its share exchange with Actinium on December 28, 2012. The transaction was accounted for as a reverse takeover/recapitalization, with Actinium treated as the accounting acquirer; the historical financial results principally reflect Actinium’s development-stage business.
The combined company is a clinical-stage biopharmaceutical business developing radioimmunotherapy cancer treatments. Its lead candidates are Actimab-A, in clinical development for acute myeloid leukemia (AML), and Iomab-B, being developed to prepare patients for hematopoietic stem cell transplantation. Neither had FDA approval or commercial sales by year-end.
Financial and operating highlights
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, net | $3.44 million | $0.32 million |
| General and administrative expense | $4.51 million | $2.96 million |
| Operating expenses | $7.95 million | $3.28 million |
| Interest expense | $1.10 million | $0.18 million |
| Net loss | $8.36 million | $3.44 million |
| Net cash used in operating activities | $5.21 million | $0.52 million |
| Net cash provided by financing activities | $5.13 million | $6.03 million |
- Cash and cash equivalents were $5.62 million at December 31, 2012, down from $5.70 million a year earlier. Current assets were $5.79 million and current liabilities were $4.64 million; reported stockholders’ equity was $1.15 million.
- Current liabilities included $3.57 million of derivative liabilities and a $140,000 note payable. The $900,000 principal convertible notes and accrued interest converted into 1,252,550 common shares in December 2012; no convertible-note carrying balance remained at year-end.
- Operating margins are not meaningful because the company had no revenue. The filing does not provide a clear standalone quarterly financial result for Q4.
Material changes versus the prior comparable period
- Net loss increased by $4.92 million year over year. The principal drivers were higher clinical-development spending, professional fees, stock-based compensation and interest expense.
- R&D expense rose to $3.44 million, primarily reflecting initiation of the multicenter Actimab-A trial and a $750,000 milestone payment to Abbott Biotherapeutics. The prior-period MSKCC reimbursement arrangement had expired in 2011.
- G&A expense increased to $4.51 million, with higher professional and payroll costs and noncash stock-based compensation contributing to the increase.
- Operating cash use rose substantially as the company expanded clinical-trial and related activities. Financing proceeds were lower than in 2011, and cash declined modestly for the year.
- The December 2012 share exchange changed Cactus from a former shell company into the public-company vehicle for Actinium’s business. The filing states that the exchange was intended to cover all Actinium equity, but reports that only about 57% had been exchanged by March 29, 2013.
Outlook, commentary, risks and unusual items
- Management estimated cash needs of up to $20 million in 2013 for R&D, manufacturing, clinical trials and working capital. It warned that failure to secure sufficient funding could delay development and focus spending on the ongoing Actimab-A trial.
- The auditor expressed substantial doubt about the company’s ability to continue as a going concern. The company had no recurring revenue, an accumulated deficit of $55.74 million, and no committed financing sufficient to address the funding need.
- Management estimated direct costs of about $7 million to complete both parts of the ongoing Actimab-A Phase I/II trial. It estimated $15–20 million for the anticipated Iomab-B pivotal trial, with completion then expected in 2015, subject to FDA input and funding.
- Key risks include early-stage clinical and regulatory uncertainty, potential adverse events, dependence on external collaborators and contract manufacturers, limited Ac-225 supply, intellectual-property and licensing exposure, and the need for additional capital that could dilute shareholders. The filing notes prolonged bone-marrow suppression at the highest Actimab-A doses in an ongoing trial, prompting dose reductions.
- In February 2013, CEO Jack Talley resigned; the company agreed to pay him $250,000 in severance and a $60,000 performance bonus, plus six months of COBRA coverage. CFO Enza Guagenti resigned in March 2013. Sergio Traversa became interim CEO and CFO, and the company was seeking permanent replacements.
- Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end, citing inadequate segregation of duties and insufficient documentation. The audit did not include an auditor attestation on internal controls.
- Other notable items include $3.57 million in Level 3 derivative liabilities and a $685,420 gain from changes in their fair value. These valuation changes affected reported results but were not operating revenue.
Important facts for investors to verify
- Reconcile the share-exchange completion and actual shares outstanding: the filing gives differing figures, including 12,053,405 shares outstanding as of March 26 (excluding certificates still being exchanged) and 21,391,665 shares on an assumed full-exchange basis.
- Confirm available cash, near-term burn and financing plans against the stated 2013 funding need of up to $20 million and the going-concern warning.
- Review the latest FDA feedback, trial enrollment, safety data and milestones for Actimab-A and Iomab-B; early results do not establish efficacy or approval prospects.
- Assess the status and terms of Ac-225 supply agreements, the proposed commercial-scale production route, and the relevant antibody and technology licenses, including associated milestones and royalties.
- Check whether the disclosed material weaknesses in financial reporting controls have been remediated and whether permanent executive leadership has been appointed.
- Evaluate dilution and potential share overhang from warrants, options, registration rights and unexchanged Actinium share certificates, as well as the limited liquidity of the OTC-traded stock.